ERBB2 and neoplasm: On the one hand, IHC and FISH are limited by sample acquisition and can only reflect the local HER2 expression level of the tumor; on the other hand, the prevalence of FISH is limited, and this test is not available in some regions due to technical limitations, with a multicenter study showing that the acceptance rate of this test among breast cancer patients is only 6%.